Mechanistic Exploration of Therapeutic Targets and Treatable Traits to Improve CNS Outcomes in People with HIV
This grant supports research to identify and validate new, modifiable therapeutic targets for improving central nervous system outcomes in people with HIV using patient data and innovative models.
Funder: National Institutes of Health
Due Dates: October 28, 2027 (Application deadline)
Funding Amounts: No cost sharing or matching required
Summary: Supports phased research to identify and experimentally validate modifiable mechanisms and therapeutic targets for HIV-associated central nervous system complications.
Key Information: Clinical trials and foreign components are not allowed.
Description
This National Institutes of Health opportunity supports research to identify modifiable mechanisms and therapeutic targets for central nervous system (CNS) complications associated with HIV. Using the R21/R33 phased research approach, the initiative begins with identifying patient phenotypes characterized by convergent pathophysiological features. It then supports discovery and experimental validation of molecular mechanisms using innovative in-vitro and in-vivo models.
The goal is to advance therapeutic target and intervention discovery that addresses the multifactorial and heterogeneous nature of HIV-associated CNS dysfunction. The opportunity is designated “Clinical Trial Not Allowed.” The National Institute of Mental Health’s Division of AIDS Research serves as the listed program contact.
